Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England

Authors: Copland, Emma;

Patone, Martina;

Saatci, Defne;

Handunnetthi, Lahiru;

Hirst, Jennifer;

Hunt, David P.J. ;

Mills, Nicholas L. ;

Moss, Paul ;

Sheikh, Aziz ;

Coupland, Carol A.C.;

Harnden, Anthony;

Robertson, Chris;

Hippisley-Cox, Julia

Source: Nature Communications

Full text

: https://doi.org/10.1038/s41467-024-47745-z

Abstract

The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.

Rights

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Cite as

Copland, E., Patone, M., Saatci, D., Handunnetthi, L., Hirst, J., Hunt, D., Mills, N., Moss, P., Sheikh, A., Coupland, C., Harnden, A., Robertson, C. & Hippisley-Cox, J. 2024, 'Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England', Nature Communications, 15, article no: 3822. https://doi.org/10.1038/s41467-024-47745-z

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1038/s41467-024-47745-z

Repository URI: https://strathprints.strath.ac.uk/89377/